In our study, we demonstrated that both empagliflozin, a SGLT2 inhibitor, and linagliptin, a DPP4 inhibitor, attenuate diabetic kidney disease by promoting glomerular autophagy in db/db mice, a model of type 2 diabetes. This evidence concerns the gene SLC5A2 and diabetic kidney disease.